Plerixafor

Generic Name
Plerixafor
Brand Names
Mozobil, Plerixafor Accord
Drug Type
Small Molecule
Chemical Formula
C28H54N8
CAS Number
110078-46-1
Unique Ingredient Identifier
S915P5499N
Background

Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer. It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune system. These stem cells are then collected and...

Indication

Plerixafor is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma.

Associated Conditions
-
Associated Therapies
Mobilization of hematopoietic stem cells
Clinical Trials
Related News

Alteration in Timing of Plerixafor Administration

Phase 2
Completed
Conditions
Autologous Transplantation
Interventions
Drug: Plerixafor
First Posted Date
2010-06-24
Last Posted Date
2013-12-13
Lead Sponsor
Emory University
Target Recruit Count
34
Registration Number
NCT01149863
Locations
🇺🇸

Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma

First Posted Date
2010-06-22
Last Posted Date
2019-12-27
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
47
Registration Number
NCT01146834
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center):, New York, New York, United States

🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

New York University Cancer Institute, New York, New York, United States

and more 2 locations

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

First Posted Date
2010-04-01
Last Posted Date
2018-01-23
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
20
Registration Number
NCT01097057
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection

Phase 2
Completed
Conditions
Myeloma
Lymphoma
Interventions
Drug: Plerixafor
First Posted Date
2010-03-30
Last Posted Date
2014-09-29
Lead Sponsor
Emory University
Target Recruit Count
45
Registration Number
NCT01095757
Locations
🇺🇸

Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

First Posted Date
2010-02-26
Last Posted Date
2017-06-28
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
1
Registration Number
NCT01076270
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

First Posted Date
2010-02-24
Last Posted Date
2013-02-15
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
18
Registration Number
NCT01074060
Locations
🇺🇸

City of Hope, Duarte, California, United States

A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation

First Posted Date
2010-02-12
Last Posted Date
2014-01-01
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
12
Registration Number
NCT01068301
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)

First Posted Date
2010-02-09
Last Posted Date
2017-03-20
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
28
Registration Number
NCT01065129
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection

Not Applicable
Conditions
Multiple Myeloma
Non-Hodgkins Lymphoma
Interventions
Drug: Plerixafor
First Posted Date
2010-01-06
Last Posted Date
2011-09-27
Lead Sponsor
Shi, Patricia, M.D.
Target Recruit Count
10
Registration Number
NCT01042717
Locations
🇺🇸

Mount Sinai School of Medicine, New York, New York, United States

Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization

Phase 2
Completed
Conditions
Lymphoma
Multiple Myeloma
Interventions
Drug: Plerixafor
First Posted Date
2009-12-23
Last Posted Date
2013-10-31
Lead Sponsor
CancerCare Manitoba
Target Recruit Count
52
Registration Number
NCT01037517
Locations
🇨🇦

CancerCare Manitoba, Winnipeg, Manitoba, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy